Molecular Signatures DOI
Ankur Bhardwaj, S. Gupta

Advances in medical diagnosis, treatment, and care (AMDTC) book series, Journal Year: 2024, Volume and Issue: unknown, P. 85 - 114

Published: Dec. 17, 2024

The discovery of biomarkers has revolutionized the field oncology, providing critical insights into processes tumour initiation and progression. Biomarkers, which can be genetic, proteomic, or metabolic in nature, serve as vital indicators for early cancer detection, prognosis, personalized treatment strategies. Tumour undergoes various stages characterized by alterations microenvironment, angiogenesis, ultimately metastasis. Understanding these at molecular level is crucial identifying reliable biomarkers. Recent advances high-throughput technologies such next-generation sequencing, mass spectrometry, advanced imaging techniques have significantly enhanced ability to discover validate new Despite promising advancements, challenges remain translation biomarker discoveries clinical practice. This chapter provides a detailed current state discovery, highlighting key findings future directions this rapidly evolving field.

Language: Английский

Targeted heart rate control using the funny current inhibitor ivabradine to reduce morbidity in patients undergoing noncardiac surgery: study protocol for a phase 2a, triple-blind, placebo-controlled randomised trial DOI Creative Commons
Bernardo Bollen Pinto, Ben Shelley, Priyanthi Dias

et al.

BJA Open, Journal Year: 2025, Volume and Issue: 13, P. 100378 - 100378

Published: Feb. 19, 2025

Language: Английский

Citations

0
Myocardial injury after non‐cardiac surgery – do patients with cancer fare worse? DOI
Chad Oughton,

Sandeep Kusre,

Walston R Martis

et al.

ANZ Journal of Surgery, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Language: Английский

Citations

0
Pharmacologic agents for perioperative cardioprotection in noncardiac surgery DOI
Waynice Neiva de Paula Garcia, Stefan De Hert

Current Opinion in Anaesthesiology, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Purpose of the review This will discuss current pharmacologic strategies for mitigation perioperative myocardial. State-of-the-art benefits and harms interventions to delineate knowledge gaps in guidelines clinical practice be presented. Recent findings Beta-blockers are known reduce major adverse cardiac events but inappropriate preoperative initiation results outcomes. Renin-Angiotensin-Aldosteron System (RAAS) inhibitors once universally discontinued before surgery now under reconsideration as continuation seems not associated with increased risk. Statins continue cornerstone due their pleiotropic effect. Continuation aspirin is supported perioperatively if bleeding risk low moderate. A few studies have investigated a strategy strict intraoperative blood pressure control failed observe meaningful effect on outcome. Whether prompt intensification treatment case diagnosis myocardial injury after noncardiac improves outcome remains established. Since MANAGE trial, no new prospectively addressed this question. Summary New data questioned previous ideas suggest more nuanced, personalized approach management. Accordingly, future should address refinement stratification, optimization strategies, development novel therapies attempting enhance outcomes high-risk surgical populations.

Language: Английский

Citations

0
Personalised perioperative dosing of ivabradine in noncardiac surgery: a single-centre, randomised, placebo-controlled, double-blind feasibility pilot trial DOI Creative Commons
Marion Jill White, Isabelle Zaccaria, Florence Ennahdi-Elidrissi

et al.

British Journal of Anaesthesia, Journal Year: 2024, Volume and Issue: 133(4), P. 738 - 747

Published: July 2, 2024

Perioperative myocardial injury after noncardiac surgery is associated with postoperative mortality. Heart rate (HR) an independent risk factor for perioperative injury. In this pilot trial we tested the feasibility of a randomised, placebo-controlled personalised HR-targeted ivabradine.

Language: Английский

Citations

3
Perioperative myocardial injury DOI
C. Hughes, Gareth L. Ackland, Ben Shelley

et al.

BJA Education, Journal Year: 2024, Volume and Issue: 24(10), P. 352 - 360

Published: Aug. 1, 2024

Language: Английский

Citations

1
Visualising myocardial injury after noncardiac surgery: a case series using postoperative cardiovascular MRI DOI Creative Commons

Dominik P. Guensch,

Jan‐Oliver Friess,

Sandra Stiffler

et al.

British Journal of Anaesthesia, Journal Year: 2024, Volume and Issue: 133(4), P. 748 - 751

Published: Aug. 2, 2024

Myocardial injury after noncardiac surgery (MINS) and perioperative myocardial are associated with increased morbidity mortality. Both diagnosed by a increase in troponin, yet there is controversy if MINS genuine insult. We applied postoperative cardiovascular magnetic resonance T2 mapping techniques to visualise acute (i.e. oedema) six patients multiple risk factors who underwent aortic surgery. The burden of oedema was substantially higher four elevated troponin qualifying for MINS, compared without MINS. data images suggest that represents injury.

Language: Английский

Citations

0
Interprétation d’une valeur élevée de troponine en dehors des syndromes coronariens aigus DOI

Maxime Carpentier,

Edith Bigot–Corbel

Revue Francophone des Laboratoires, Journal Year: 2024, Volume and Issue: 2024(566), P. 18 - 26

Published: Nov. 1, 2024

Citations

0
Molecular Signatures DOI
Ankur Bhardwaj, S. Gupta

Advances in medical diagnosis, treatment, and care (AMDTC) book series, Journal Year: 2024, Volume and Issue: unknown, P. 85 - 114

Published: Dec. 17, 2024

The discovery of biomarkers has revolutionized the field oncology, providing critical insights into processes tumour initiation and progression. Biomarkers, which can be genetic, proteomic, or metabolic in nature, serve as vital indicators for early cancer detection, prognosis, personalized treatment strategies. Tumour undergoes various stages characterized by alterations microenvironment, angiogenesis, ultimately metastasis. Understanding these at molecular level is crucial identifying reliable biomarkers. Recent advances high-throughput technologies such next-generation sequencing, mass spectrometry, advanced imaging techniques have significantly enhanced ability to discover validate new Despite promising advancements, challenges remain translation biomarker discoveries clinical practice. This chapter provides a detailed current state discovery, highlighting key findings future directions this rapidly evolving field.

Language: Английский

Citations

0